Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Flexner

Showing results (131-140 of 137) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 137 results.
Clinical Pharmacology and Therapeutics|February 18, 2026
Accelerating Generic Long-Acting Antiretrovirals for Global HIV Treatment: Workshop Findings and a Roadmap to AccessUsman Arshad, Lobna Gaayeb, Henry Pertinez, et al.
Open Forum Infectious Diseases|July 9, 2025
Virology Outcomes of Tenofovir-lamivudine-dolutegravir in Treatment-naïve and Virologically Suppressed Individuals Switching From an NNRTI-based Regimen: An Observational Analysis at 13 SitesCissy Kityo, Caitlyn McCarthy, Serena P Koenig, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 3, 2023
Interleukin 6 Blockade With Tocilizumab Diminishes Indices of Inflammation That Are Linked to Mortality in Treated Human Immunodeficiency Virus InfectionNicholas T Funderburg, Carey L Shive, Zhengyi Chen, et al.
The Lancet. HIV|June 27, 2025
Evaluation of antiretroviral regimen switching options in adults with HIV with sustained viral load non-suppression on dolutegravir, lamivudine, and tenofovir in eastern, central, southern, and western Africa: a modelling studyAndrew N Phillips, Loveleen Bansi-Matharu, Joep J van Oosterhout, et al.
The Lancet. HIV|November 28, 2025
Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort studyJean Bernard Marc, Caitlyn McCarthy, Carole L Wallis, et al.
The Lancet. HIV|January 15, 2023
Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling studyJennifer Smith, Loveleen Bansi-Matharu, Valentina Cambiano, et al.
The Lancet. HIV|July 11, 2020
Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility studyChristine M Durand, Adam A Capoferri, Andrew D Redd, et al.
Pageof 14

Showing results (131-140 of 137) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 137 results.
Clinical Pharmacology and Therapeutics|February 18, 2026
Accelerating Generic Long-Acting Antiretrovirals for Global HIV Treatment: Workshop Findings and a Roadmap to AccessUsman Arshad, Lobna Gaayeb, Henry Pertinez, et al.
Open Forum Infectious Diseases|July 9, 2025
Virology Outcomes of Tenofovir-lamivudine-dolutegravir in Treatment-naïve and Virologically Suppressed Individuals Switching From an NNRTI-based Regimen: An Observational Analysis at 13 SitesCissy Kityo, Caitlyn McCarthy, Serena P Koenig, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 3, 2023
Interleukin 6 Blockade With Tocilizumab Diminishes Indices of Inflammation That Are Linked to Mortality in Treated Human Immunodeficiency Virus InfectionNicholas T Funderburg, Carey L Shive, Zhengyi Chen, et al.
The Lancet. HIV|June 27, 2025
Evaluation of antiretroviral regimen switching options in adults with HIV with sustained viral load non-suppression on dolutegravir, lamivudine, and tenofovir in eastern, central, southern, and western Africa: a modelling studyAndrew N Phillips, Loveleen Bansi-Matharu, Joep J van Oosterhout, et al.
The Lancet. HIV|November 28, 2025
Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort studyJean Bernard Marc, Caitlyn McCarthy, Carole L Wallis, et al.
The Lancet. HIV|January 15, 2023
Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling studyJennifer Smith, Loveleen Bansi-Matharu, Valentina Cambiano, et al.
The Lancet. HIV|July 11, 2020
Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility studyChristine M Durand, Adam A Capoferri, Andrew D Redd, et al.
Pageof 14